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Conclusions. Patients diagnosed as having breast cancer were neither depressed nor anxious during adjuvant radiotherapy.
Sexuality is the most affected issue of quality of life (40%). We will develop sexuality workshops as an area of improvement.
http://dx.doi.org/10.1016/j.rpor.2013.03.591
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Objective. The objective of this study is to assess the quality of life (QL) and mood in patients treated with radiotherapy.
Materials and methods. Descriptive, prospective, longitudinal single center pilot study approved by our center’s Ethical Committee
for Clinical Research. We obtained a sample of 40 patients with an estimated loss of 5 patients. Patient selection was carried out
from May to September 2012 in a consecutive, non-probabilistic manner. SPSS v15 was used for statistical analysis. The study
was performed using the EORTC QLQ-C30 test to evaluate QL and the HAD test to asses mood disorders. These two tests were
carried before and upon completion of the radiotherapy treatment.
Results. Of the 40 patients that began our study, 4 failed to complete the study due to lack of cooperation (3 patients) and exitus
(1 patient). Of the remaining 36, 15 (37%) were diagnosed with breast cancer, 12 (30%) with prostate cancer, 5 (13%) with head
and neck cancer and 4 (10%) with other locations. Mean age was 53 (24–82). By genders, 17 (42%) were women and 23 (58%)
were men. Of the tests carried out, only one parameter proved to be statistically signiﬁcant (p=0.041), the emotional function
of the QLQ-C30, with an initial value of 75.00 (22.91) and a ﬁnal value of 83.33 (16.67). All other parameters analyzed did not
reach statistical signiﬁcance. With a tendency in regard to P50, in the subscale of symptoms, pain (P50=25−16.67) and insomnia
(P50=16.67−0) showed a decrease upon treatment completion, whereas fatigue increased by the end of radiotherapy treatment
(P50=22.22–33.33). All other symptoms did not show any remarkable alterations.
Conclusions. Radiotherapy treatment represents a stress factor in the patient’s mood, worsening its emotional function and
therefore creating an adaptative response which leads to symptoms of anxiety and depression. In order to reach statistically
signiﬁcant differences in the other parameters assessed, a larger patient sample is needed.
http://dx.doi.org/10.1016/j.rpor.2013.03.592
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Introduction. Oral mucositis is a common problem in cancer patients and it is often associated with treatment of radio and/or
chemotherapy. It is a painful condition, with great impact on the quality of life of patients and can lead to discontinuation of
treatment, with treatment failure that entails. OTFC is indicated for the treatment of breakthrough cancer pain and may be
beneﬁcial for the treatment of this condition.
Objectives. Assess the effectiveness and tolerability of OTFC in patients with oral mucositis induced by radiotherapy.
Methods. An open-label, prospective, observational study of the effectiveness of OTFC in 90 patients with grade 2–3 or 4 oral
mucositis, produced by radiation therapy. All of them were receiving concomitant chemotherapy (with platinum or taxanes). The
treatment was assessed by determining the degree of RT treatment interruption due to pain and the possibility of maintaining
nutritional support for the patient. Adverse effects attributable to OTFC were also reported.
Results. No patient discontinued RT treatment for pain. All patients were able to maintain the nutritional support. There were no
adverse effects attributable to OTFC.
Conclusions. OTFC can be considered a safe and effective option in the treatment of pain in these patients, avoiding treatment
interruptions and facilitating nutritional support.
http://dx.doi.org/10.1016/j.rpor.2013.03.593
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Purpose. To evaluate the results of the use of percutaneous endoscopic gastrostomy (PEG) during radiotherapy in patients with
head and neck cancer.
Materials and methods. We included 84 patients, 72 men and 12 women, mean aged 55 years (range 33–70), with head and neck
cancer, predominantly in the oropharynx; 82.14% were locally advanced (stages III–IV), and 17.86% in stages I–II. Radical 3D
radiotherapy was performed (September 2003–September 2010) with concurrent chemotherapy. Prophylactic PEG was indicated
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in cases of high risk of mucositis, and the procedure was done before the start of treatment in 41.7% (81% before the appearance
of any degree of mucositis). The patients kept PEG for an average of 6.6 months in 67.86% (range 2–32) and in 32.14% indeﬁnitely.
Blender diet by gastrostomy was indicated in 64%, and nutritional supplements in 18%. 7% maintained oral feeding throughout
treatment and did not use PEG. Toxicity was assessed according to RTOG scale.
Results. After mean follow up of 56.5 months (range 24–108), 48.8% of patients were alive; 51.2% died (62.8% of progression
or recurrence), with median survival of 17.8 months (range 3–60). 18% of the patients began using PEG with an average dose of
31.5Gy (range 14–52). 50.1% had weight loss >5% and 31% less than or equal to 5%. Most dermatitis and mucositis were grade 2. All
minor and major complications were 20.2% and 1.2% respectively (among the majors, there was one wall abscess). Radiotherapy
treatment was discontinued in only one patient.
Conclusions. In our series,we foundminor complications rates similar to those previously reported, and lowermajor complications
rates. Our patients probably had a good degree of tolerance and satisfaction about PEG because they used it early despite the
mild or moderate mucosal toxicity and only a small percentage did not use it. The moderate weight loss they presented may be
due to advanced disease, combined therapies and lack of indication of enteral speciﬁc diet. In our experience, gastrostomy is a
safe nutritional support measure that facilitates the management of toxicity in patients with head and neck cancer and helps
to fulﬁll cancer treatment without interruption.
http://dx.doi.org/10.1016/j.rpor.2013.03.594
